CytoDyn Inc.
CYDY · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.05 | 0.07 | 0.04 | -0.03 |
| FCF Yield | -2.14% | -7.11% | -11.47% | -33.77% |
| EV / EBITDA | 49.20 | -10.07 | -6.23 | -1.35 |
| Quality | ||||
| ROIC | -45.06% | 41.89% | 54.87% | 252.43% |
| Gross Margin | 0.30% | 0.00% | 0.00% | 80.08% |
| Cash Conversion Ratio | -2.34 | 0.22 | 0.31 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | – | – |
| Free Cash Flow Growth | 20.19% | 56.26% | 67.69% | 33.96% |
| Safety | ||||
| Net Debt / EBITDA | 1.79 | -1.50 | -0.81 | -0.17 |
| Interest Coverage | 2.33 | -2.08 | -1.61 | -2.77 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -298,044.51 | -372,060.86 | -130,826.43 | -344,649.53 |